Mission Therapeutics a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target DUBs, which are in Phase I development.